Allogene reports Q1 net loss $79.9M, cash $733M; plans pivotal ALLO-501A trial mid-2022

Allogene Therapeutics, Inc.

2022-Q1 EPS reported -$0.56 revenue$61,000

Net loss $79.9M ($0.56/sh); R&D $60.2M, G&A $19.9M; cash $733.1M at March 31, 2022.
Pivotal Phase 2 ALPHA2 trial of ALLO-501A in R/R large B cell lymphoma to start mid-2022 using CF1 product.
FDA granted Orphan Drug Designation for ALLO-605 (TurboCAR) for multiple myeloma; Fast Track for ALLO-316 for RCC.
Full-year 2022 GAAP OpEx guided at $360-390M, including $90-100M stock-based compensation.
Cell Forge 1 operational; projected annual capacity of ~20,000 AlloCAR T doses at scale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.